BioAge Labs, Inc. filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the fiscal quarter ended September 30, 2026, disclosing balance sheet data, share counts, and pipeline status for the Emeryville, California-based biotechnology company trading on NASDAQ:BIOA.

Key Highlights

  • Shares outstanding: As of October 30, 2026, the company reported 45,958,509 shares of common stock outstanding.
  • Total assets: Total assets were $367,648 thousand as of September 30, 2026, up from $294,889 thousand as of December 31, 2025.
  • Accumulated deficit: The accumulated deficit stood at $415,270 thousand as of September 30, 2026, compared to $333,416 thousand at December 31, 2025.
  • Cash and marketable securities: Cash and cash equivalents were $52,666 thousand, with current marketable securities of $230,971 thousand and non-current marketable securities of $68,680 thousand as of September 30, 2026.
  • Stockholders' equity: Total stockholders' equity was $346,446 thousand as of September 30, 2026, versus $272,051 thousand at December 31, 2025.
  • Additional paid-in capital: Additional paid-in capital increased to $762,883 thousand from $605,189 thousand at December 31, 2025.

BioAge Labs Balance Sheet and Financial Position for September 30, 2026

According to the filing, BioAge Labs reported total assets of $367,648 thousand as of September 30, 2026, an increase from $294,889 thousand at December 31, 2025. The company's current assets totaled $295,054 thousand, with cash and cash equivalents of $52,666 thousand and current marketable securities of $230,971 thousand. The filing also noted non-current marketable securities of $68,680 thousand, up from $4,032 thousand at year-end 2025.

The company disclosed total liabilities of $21,202 thousand as of September 30, 2026, down from $22,838 thousand at December 31, 2025. Among notable changes, the filing showed the current portion of the term loan was zero at September 30, 2026, compared to $2,648 thousand at December 31, 2025. Deferred revenue decreased to $4,632 thousand from $5,754 thousand over the same period. The warrant liability declined to $164 thousand from $370 thousand.

The accumulated deficit grew to $415,270 thousand from $333,416 thousand at December 31, 2025, reflecting ongoing operating losses. Additional paid-in capital rose to $762,883 thousand from $605,189 thousand, and shares issued and outstanding increased to 45,951,078 from 37,386,908, according to the filing. The company identified itself as a non-accelerated filer, smaller reporting company, and emerging growth company. The filing noted that it contains forward-looking statements that "are subject to a number of known and unknown risks, uncertainties, and assumptions," and are the company's own projections subject to its cautionary language.

What Was Disclosed

BioAge Labs filed its Form 10-Q for the quarter ended September 30, 2026, disclosing balance sheet figures showing increased total assets, a higher accumulated deficit, and an expanded share count relative to December 31, 2025. The filing identified product candidates BGE-102 and APJ programs as active pipeline assets.